31 results about "Ponatinib" patented technology

The present disclosure relates to polymorphic forms of the hydrochloride salt of ponatinib (“compound 1”) and to processes for the preparation of these polymorphic forms. The present disclosure also generally relates to a pharmaceutical composition comprising the forms, as well of methods of using the form(s) in the treatment of disorders associated with pathological cellular proliferation, such as neoplasms, and cancer.

The invention belongs to the technical field of kidney injury treatment drugs, and particularly relates to application of ponatinib as a drug for acute kidney injury. As an acute clinical complication, the acute kidney injury has the characteristics of being high in morbidity and high in mortality, and effective treatment drugs are not achieved at present. Related researchers in the field show that PDCD4 expression becomes higher in an acute kidney injury model, and it is indicated that the PDCD4 plays an important role in the physiological mechanism related to the acute kidney injury. The situation that the PDCD4 aggravates the kidney injury by regulating an Fgr-Stat3-Notch1 pathway is further confirmed. The confirmation of the regulatory mechanism provides a basis for the treatment of the acute kidney injury. According to the research results, the ponatinib, an Fgr kinase inhibitor, is adopted to treat the acute kidney injury, the drug has a significant protective effect on the injury caused by kidney ischemia reperfusion, and it is indicated that the drug intervention in Fgr can prevent and treat the acute kidney injury.

The invention relates to a preparation method of a drug for treating chronic granulocytic leukemia, belonging to the field of medical chemistry, and specifically relates to a preparation method of 3-[2-(imidazo[1,2-b] pyridazine-3-yl) acetenyl]-4-methyl-N-{4-[4-methyl piperazine-1-yl] methyl}-3- trifluoromethyl phenyl} benzoyl amide (ponatinib). The method comprises the following steps: adding a phosphine ligand and cesium carbonate at the same time by taking Pd(PPh3)2Cl2 as a catalyst; adding strong base DBU or adding CuI as a cocatalyst to carry out sonagashira reaction, wherein the phosphine ligand is selected from tricyclohexyl phosphine (PCy3), tri-tert-butyl phosphine (PtBu3) or tri(funan-2-yl) phosphine (P(2-furyl)3). The method disclosed by the invention is complete in reaction, does not have or has extremely few diyne byproduct of alkyne coupling, and is easy to separate and purity.

The invention belongs to the technical field of organic catalysis and in particular relates to a clean production method of a medicine ponatinib intermediate for treating leukemia. According to the clean production method provided by the invention, cerium nitrate is used as a modifying agent and hectorite is modified through a co-precipitation method to obtain modified hectorite; then noble metalPd is loaded to obtain a cerium modified hectorite supported Pd catalyst. The catalyst prepared by the clean production method can be used for catalyzing 4-(4-methylpiperazine-1-methylene)-3-trifluoromethyl-1-nitrobenzene to prepare the medicine ponatinib intermediate for treating the leukemia, i.e., 3-trifluoromethyl-4-[(4-methylpiperazine-1-yl)methyl]aniline. The clean production method has theadvantages of green and pollution-free catalysis system and relatively high yield and has an industrialized production prospect.

The invention belongs to the field of pharmaceutical preparation, and in particular relates to application of Ponatinib in preparing drugs for treating fungal infections. Ponatinib has a therapeutic effect on fungal infections, especially when used in combination with fluonazole, not only has a good fungistatic effect, but also achieves a fungicidal effect against fungal infections; and furthermore, Ponatinib has a broad-spectrum antifungal effect, and has good killing effects on fluconazole-resistant Candida albicans strains, Cryptococcus neoformans and Saccharomyces cerevisiae. According tothe present invention, a gene PDR5 and a gene PMA1 are found to be drug targets of Ponatinib for antifungal infection effect, and a new development direction and action mechanism for the treatment offungal infections and research and development of therapeutic drugs are provided.

The invention relates to a drug for preventing and treating cerebral cavernous malformation (CCM). The invention discloses a drug which inhibits molecular passages of the CCM to further inhibit occurrence and growth of CCM focuses, and the drug is Ponatinib and also comprises analogues or derivatives of Ponatinib.

The invention discloses application of ponatinib in the preparation of a medicine for treating ischemia/reperfusion injury. By using ponatinib in treating ischemia/reperfusion injury, especially in treating brain tissue neuropathy and even especially in the protective effect on ischemic cerebral apoplexy, cerebral ischemia/reperfusion injury can be remarkably mitigated.

Provided herein are compositions and methods for preventing or reversing T cell exhaustion. In particular, the present invention relates to methods of preventing or reversing T cell exhaustion by exposing T cells experiencing T cell exhaustion to particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib), or by expanding genetically engineered T cells in the presence of particular tyrosine kinase inhibitors (e.g., dasatinib, ponatinib).

The invention discloses application of a 2-cyano phenalenone compound in preparation of drugs for treating drug-resistant tumors, and belongs to the technical field of medical chemistry. The 2-cyano phenalenone compound disclosed by the invention can induce apoptosis of tumor cells resistant to chemotherapeutic drugs such as cis-platinum and adriamycin and targeted anticancer drugs such as ponatinib, tamoxifen and Winatocork, so that the effects of inhibiting growth of the chemotherapeutic drugs and the targeted anticancer drug resistant cells and killing the chemotherapeutic drugs and the targeted anticancer drug resistant cells are achieved; the compound is an apoptosis inducer with very high activity, and can be used for preparing potential drugs for preventing and treating chemotherapeutic drugs and targeted anticancer drug-resistant tumors.

The invention relates to application of micafungin in the preparation of an anti-tumor drug and an anti-tumor drug. Micafungin can promote the death of tumor cells and inhibit the growth of tumor cells, and has an anti-tumor effect. Mikafungin can enhance the anti-tumor effect of other anti-tumor drugs when combined with the anti-tumor drugs, especially combined with cytotoxic anti-tumor drugs such as drugs that affect DNA structure and function such as cisplatin, drugs that interfere with the transcription process and prevent RNA synthesis such as doxorubicin, tyrosine kinase inhibitors suchas ponatinib and/or pazopanib, and drugs that inhibit protein synthesis and function such as paclitaxel. The Mikafungin can enhance the anti-tumor effect of these drugs.

A method for preventing, treating and/or improving a prostatic disease or disorder associated with epithelial hyperplasia and/or fibrosis, comprising: administering an effective amount of a multikinase inhibitor to a subject in need thereof, wherein the multikinase inhibitor has a certain spectrum of kinase inhibitory activity. The multikinase inhibitor is sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and/or lenvatinib. The prostatic disease or disorder is selected from the group consisting of benign prostate hyperplasia and its associated lower urinary tract symptoms, fibrosis of ureters and renal pelvis, prostate adenoma, and prostatic intraepithelial neoplasia in animals and humans.